Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Sclerosis, SystemicMesenchymal Stem Cells
Interventions
BIOLOGICAL

UCMSC

Each infusion will consist of 1 million MSC/kg suspended in 50 mL of PlasmaLyte A.

OTHER

Placebo

Each infusion will consist of 50 mL of PlasmaLyte A.

Trial Locations (1)

H3T 1E2

RECRUITING

Sir Mortimer B. Davis Jewish General Hospital, Montreal

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Université de Montréal

OTHER

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

collaborator

University Paris 7 - Denis Diderot

OTHER

lead

Marie Hudson, MD

OTHER